Doxazosin Tablet
Product Images NDC 50268-223

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50268-223). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (222 15)

Label for Doxazosin Tablets, USP 1 mg oral tablets by AvPAK. The label indicates a package of 50 tablets (5 x 10 unit doses) for prescription use only. It includes storage instructions, pharmacist dispensing information, manufacturer location in Pulaski, TN, and the AvPAK logo.*

FDA Label Image

2 (223 15)

Doxazosin Tablets, USP 2 mg oral tablets, prescription only. Package contains 50 tablets (5 bottles of 10 tablets each). Label includes storage instructions, pharmacist dispensing guidance, and manufacturer AvPAK information with contact details and logo.*

FDA Label Image

4 (224 15)

Doxazosin Tablets, USP 4 mg oral tablets label showing packaging for 50 tablets (5 x 10 unit dose) by AvPAK. The label includes dosage strength, Rx only designation, storage instructions, pharmacist dispensing info, and manufacturer details for AvKARE in Pulaski, TN. The label features a barcode and the AvPAK logo.*

FDA Label Image

8 (225 15)

Label for Doxazosin Tablets USP 8 mg oral tablets, containing 50 tablets in a unit dose pack (5 x 10). The label indicates prescription use only, manufacturer AvPAK, with storage instructions and a barcode shown. Additional labeling includes a pharmacist dispensing note and usual dosage directions reference.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure of doxazosin depicted in a molecular diagram, showing its detailed atomic composition and bonding, including methoxy groups, an amino group, a piperazine ring, and a benzodioxane moiety with a methanesulfonate component.*

FDA Label Image

Figure1.jpg (Figure1)

Two line graphs depicting clinical study results of Doxazosin versus placebo over 14 weeks. The left graph shows mean change in total symptom score from baseline, with Doxazosin demonstrating a greater symptom score reduction than placebo. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline, where Doxazosin shows higher flow rate improvements compared to placebo. Both graphs include error bars and indicate statistical significance at various time points.*

FDA Label Image

Table3.jpg (Table3)

A data table summarizing effectiveness data from placebo-controlled trials of Doxazosin in various doses (4 mg and 8 mg) versus placebo. It details symptom score and maximum flow rate measurements, their baseline and mean changes, annotated with statistical significance. The adjacent bar graph visually compares maximum flow rate and symptom score changes across placebo and Doxazosin doses in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.